Successful initiation of trial for new device designed to treat patients
who suffer from refractory angina
MONTREAL, Feb. 23 /CNW Telbec/ - The interventional cardiology team at
the Montreal Heart Institute (MHI) recently began patient enrolment for
a new device, the Neovasc ReducerTM, designed to treat patients suffering from refractory angina. The
treatment method is a first in North America and is being conducted as
part of an international study, the COSIRA trial. This innovative
treatment is promising for thousands of Canadians disabled by
refractory angina and who lack alternatives for relieving their
symptoms and improving their quality of life.
Developed in Canada by Neovasc Inc. (TSX Venture: NVC), the Reducer is
implanted in the coronary sinus vein using minimally invasive
techniques. Placement of the device is performed using a procedure that
is similar to implanting a coronary stent and takes approximately 20
minutes. The Reducer is designed to establish a permanent and
controlled narrowing of the coronary sinus, which is a new technique to
provide relief of refractory angina symptoms by altering blood flow in
the coronary sinus and thereby increasing perfusion of oxygenated blood
to certain areas of the heart muscle that receive an inadequate supply
of oxygen. Patients are discharged within 24 hours after the
This landmark procedure was carried out by a MHI multidisciplinary team
composed of Drs. Marc Jolicoeur, Serge Doucet and Jean-François
Tanguay, interventional cardiologists, as well as Dr. Raymond Cartier,
heart surgeon. "All the initial cases have gone very well and we are
optimistic that the long term results of the procedure will be
favourable" says Dr. Marc Jolicoeur who is also assistant professor in
the faculty of medicine at the Université de Montréal. "This new method
to treat refractory angina safely provides care for patients who cannot
be helped with conventional drug, catheter or surgical therapy."
The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina)
trial is a multicenter, sham-controlled, randomized, double-blinded
study of the Reducer that is expected to enroll up to 124 patients. The
primary endpoint is efficacy in reducing angina symptoms after six
months. In addition to the Montreal Heart Institute, the COSIRA trial
is also enrolling patients at the University of Ottawa Heart Institute,
the Antwerp Cardiovascular Institute and Ziekenhuis Oost-Linburg
Hospital in Belgium; and Ultrecht Medical Center in the Netherlands.
Additional sites are expected to join the trial in the coming months.
Results from the initial first-in-man clinical trial of the Reducer were
presented at the American College of Cardiology 2010 annual meeting.
The data showed that three years after implantation of the Reducer, the
product remained safe and the majority of the 15 patients treated
continued to show measurable improvement in angina symptoms.
About refractory angina
Refractory angina is a painful and debilitating condition that occurs
when the coronary arteries deliver an inadequate supply of blood to the
heart muscle. It currently affects over two million patients worldwide,
who typically lead severely restricted lives and current treatment
options are limited. The incidence of refractory angina is currently
growing as better treatments for coronary artery disease reduce
mortality and increase number of patients with advanced disease.
About the Montreal Heart Institute
Founded in 1954 by Dr. Paul David, the Montreal Heart Institute
constantly aims for the highest standards of excellence in the
cardiovascular field through its leadership in prevention,
ultra-specialized care, training of professionals, clinical and
fundamental research, and assessment of new technologies. It is
affiliated with the Université de Montréal and its clinical outcomes
are among the best in the world.
To learn more about the Institute, please visit our website at www.icm-mhi.org.
About Neovasc Inc.
Neovasc Inc. is a specialty vascular device company that develops,
manufactures and markets medical devices for the rapidly growing
vascular and surgical marketplace. Current products include the Neovasc
Reducer™, a novel product in development to treat refractory angina,
and a line of advanced biological tissue technologies that are used to
enhance surgical outcomes and as key components in a variety of
third-party medical products, including transcatheter heart valves.
For more information, visit: www.neovasc.com
SOURCE MONTREAL HEART INSTITUTE
For further information:
Montreal Heart Institute
514 376-3330, ext. 2641